Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft

Nature Communications

Volumn 7, Issue , 2016, Pages

  Mohiuddin, Muhammad M ^a   Singh, Avneesh K ^a   Corcoran, Philip C ^a   Thomas Iii, Marvin L ^b   Clark, Tannia ^c   Lewis, Billeta G ^b   Hoyt, Robert F ^d   Eckhaus, Michael ^b   Pierson Iii, Richard N ^e   Belli, Aaron J ^f   Wolf, Eckhard ^g   Klymiuk, Nikolai ^g   Phelps, Carol ^h   Reimann, Keith A ^f   Ayares, David ^h   Horvath, Keith A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MUNICH   (Germany)

^h REVIVICOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CEFAZOLIN; GANCICLOVIR; HEPARIN; MEMBRANE COFACTOR PROTEIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHA CD40; MYCOPHENOLATE MOFETIL; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; THROMBOMODULIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ALPHA-1,3-GALACTOSYLTRANSFERASE 1, PORCINE; ANTIBODY; CD40 ANTIGEN; CD46 PROTEIN, HUMAN; GALACTOSYLTRANSFERASE; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; THBD PROTEIN, HUMAN;

ANTIBODY; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP; DRUG; GENE EXPRESSION; GENETIC ENGINEERING; PIG; PROTEIN; SURVIVAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GALACTOSYLTRANSFERASE GENE KNOCKOUT PIG; GENE CONSTRUCT; GENE INACTIVATION; GRAFT FAILURE; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM SURVIVAL; MALE; NONHUMAN; PAPIO ANUBIS; PROTEIN EXPRESSION; TELEMETRY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BABOON; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PIG; PROCEDURES; TRANSGENE; TRANSGENIC ANIMAL; XENOGRAFT;

PAPIO; PRIMATES; SUIDAE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; ANTIGENS, CD40; ANTIGENS, CD46; ANTILYMPHOCYTE SERUM; FEMALE; GALACTOSYLTRANSFERASES; GENE EXPRESSION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; MYCOPHENOLIC ACID; PAPIO; RITUXIMAB; SWINE; THROMBOMODULIN; TRANSGENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84963649631     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11138     Document Type: Article

References (31)

1. Kobayashi, T. et al. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation 64, 1255-1261 (1997).
2. Bach, F. H., Winkler, H., Ferran, C., Hancock, W. W. and Robson, S. C. Delayed xenograft rejection. Immunol.Today 17, 379-384 (1996).
3. Byrne, G. W. et al. Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival. Transplantation 82, 1787-1791 (2006).
4. Kuwaki, K. et al. Heart transplantation in baboons using alpha1, 3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat. Med. 11, 29-31 (2005).
5. Mohiuddin, M. M. et al. B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8 months. Am. J. Transplant. 12, 763-771 (2012).
6. Mohiuddin, M. M. et al. Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation. J. Thorac. Cardiovasc. Surg. 148, 1106-1113 discussion 1113-1104 (2014).
7. Mohiuddin, M. M. et al. Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model. Xenotransplantation 21, 35-45 (2014).
8. Wu, G. et al. Co-stimulation blockade targeting CD154 and CD28/B7 modulates the induced antibody response after a pig-to-baboon cardiac xenograft. Xenotransplantation 12, 197-208 (2005).
9. Michler, R. E., McManus, R. P., Smith, C. R., Sadeghi, A. N. and Rose, E. A. Technique for primate heterotopic cardiac xenotransplantation. J. Med. Primatol. 14, 357-362 (1985).
10. Novitzky, D., Cooper, D. K. and Barnard, C. N. The surgical technique of heterotopic heart transplantation. Ann. Thorac. Surg. 36, 476-482 (1983).
11. Wuensch, A. et al. Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs. Transplantation 97, 138-147 (2014).
12. Ayares, D. et al. Genetic engineering of source pigs for xenotransplantation: progress and prospect. Xenotransplantation 20, 361 (2013).
13. Lowe, M. et al. In vivo characterization of novel non-depleting anti-CD40 monoclonal antibodies in nonhuman primates. Am. J. Transplant. 11, 474 (2011).
14. Horvath, K. A. et al. Left ventricular pressure measurement by telemetry is an effective means to evaluate transplanted heart function in experimental heterotopic cardiac xenotransplantation. Transplant. Proc. 42, 2152-2155 (2010).
15. Hisashi, Y. et al. Rejection of cardiac xenografts transplanted from alpha1, 3-galactosyltransferase gene-knockout (GalT-KO) pigs to baboons. Am. J. Transplant. 8, 2516-2526 (2008).
16. Kuwaki, K. et al. Localized myocardial infarction following pig-to-baboon heart transplantation. Xenotransplantation 12, 489-491 (2005).
17. Ibrahim, Z. et al. Selected physiologic compatibilities and incompatibilities between human and porcine organ systems. Xenotransplantation 13, 488-499 (2006).
18. Soin, B. et al. Physiological aspects of pig-to-primate renal xenotransplantation. Kidney Int. 60, 1592-1597 (2001).
19. Lelovas, P. P., Kostomitsopoulos, N. G. and Xanthos, T. T. A comparative anatomic and physiologic overview of the porcine heart. J. Am. Assoc. Lab. Anim. Sci. 53, 432-438 (2014).
20. Byrne, G. W. et al. Transgenic pigs expressing human CD59 and decayaccelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 63, 149-155 (1997).
21. Cozzi, E. and White, D. J. G. The generation of transgenic pigs as potential organ donors for humans. Nat. Med. 1, 964-966 (1995).
22. Buhler, L. et al. Pig kidney transplantation in baboons: anti-Gal(alpha)1-3 Gal IgM alone is associated with acute humoral xenograft rejection and disseminated intravascular coagulation. Transplantation 72, 1743-1752 (2001).
23. Iwase, H. et al. Pig-to-baboon heterotopic heart transplantation-exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens. Xenotransplantation 22, 211-220 (2015).
24. Milland, J., Christiansen, D. and Sandrin, M. S. Alpha1,3-galactosyltransferase knockout pigs are available for xenotransplantation: are glycosyltransferases still relevant? Immunol. Cell Biol. 83, 687-693 (2005).
25. Chen, G. et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat. Med. 11, 1295-1298 (2005).
26. Shimizu, A. et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase geneknockout pigs in baboons. Am. J. Pathol. 172, 1471-1481 (2008).
27. Salama, A., Evanno, G., Harb, J. and Soulillou, J. P. Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation. Xenotransplantation 22, 85-94 (2015).
28. Springer, S. A., Diaz, S. L. and Gagneux, P. Parallel evolution of a self-signal: humans and new world monkeys independently lost the cell surface sugar Neu5Gc. Immunogenetics 66, 671-674 (2014).
29. Pierson, 3rd R. N. et al. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation 16, 263-280 (2009).
30. Byrne, G. W., Stalboerger, P. G., Du, Z., Davis, T. R. and McGregor, C. G. Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation 91, 287-292 (2011).
31. McGregor, C. G. et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J. Thorac. Cardiovasc. Surg. 130, 844-851 (2005).